News
Innovation Passport awarded Alnylam and its hypertension therapy
Alnylam Pharmaceuticals has announced that zilebesiran – an investigational RNAi therapy targeting liver-expressed angiotensinogen – has been awarded an Innovation Passport for the treatment of hypertension by the Medicines and Healthcare products Regulatory Agency (MHRA).